| . | Crohn’s Disease . | . | Ulcerative Colitis . | . | IBD Unclassified . | . | Total . | . |
|---|---|---|---|---|---|---|---|---|
| . | N . | % . | N . | % . | N . | % . | N . | % . |
| . | 2003 . | 100.0% . | 974 . | 100.0% . | 52 . | 100.0% . | 3029 . | 100.0% . |
| At time of enrollment | ||||||||
| Aminosalicylates | 169 | 8.4% | 350 | 35.9% | 17 | 32.7% | 536 | 17.7% |
| Mesalamine | 132 | 6.6% | 301 | 30.9% | 15 | 28.8% | 448 | 14.8% |
| Sulfasalazine | 31 | 1.5% | 37 | 3.8% | 2 | 3.8% | 70 | 2.3% |
| Balsalazide | 9 | 0.4% | 28 | 2.9% | 0 | 0.0% | 37 | 1.2% |
| Biologics | 1147 | 57.3% | 372 | 38.2% | 19 | 36.5% | 1538 | 50.8% |
| Infliximab | 365 | 18.2% | 173 | 17.8% | 6 | 11.5% | 544 | 18.0% |
| Adalimumab | 335 | 16.7% | 64 | 6.6% | 6 | 11.5% | 405 | 13.4% |
| Vedolizumab | 167 | 8.3% | 115 | 11.8% | 4 | 7.7% | 286 | 9.4% |
| Ustekinumab | 236 | 11.8% | 9 | 0.9% | 2 | 3.8% | 247 | 8.2% |
| Certolizumab Pegol | 39 | 1.9% | 2 | 0.2% | 1 | 1.9% | 42 | 1.4% |
| Golimumab | 3 | 0.1% | 9 | 0.9% | 0 | 0.0% | 12 | 0.4% |
| Natalizumab | 2 | 0.1% | 0 | 0.0% | 0 | 0.0% | 2 | 0.1% |
| Immunomodulators | 458 | 22.9% | 221 | 22.7% | 13 | 25.0% | 692 | 22.8% |
| Azathioprine | 254 | 12.7% | 135 | 13.9% | 5 | 9.6% | 394 | 13.0% |
| Methotrexate | 115 | 5.7% | 34 | 3.5% | 6 | 11.5% | 155 | 5.1% |
| Mercaptopurine | 86 | 4.3% | 28 | 2.9% | 0 | 0.0% | 114 | 3.8% |
| Tofacitinib | 4 | 0.2% | 22 | 2.3% | 1 | 1.9% | 27 | 0.9% |
| Tacrolimus | 1 | 0.0% | 3 | 0.3% | 1 | 1.9% | 5 | 0.2% |
| Steroid Therapies | 151 | 7.5% | 111 | 11.4% | 5 | 9.6% | 267 | 8.8 |
| Exposure | ||||||||
| Aminosalicylates | 898 | 44.8% | 612 | 62.8% | 38 | 73.1% | 1548 | 51.1% |
| Mesalamine | 829 | 41.4% | 587 | 60.3% | 37 | 71.2% | 1453 | 48.0% |
| Sulfasalazine | 195 | 9.7% | 134 | 13.8% | 12 | 23.1% | 341 | 11.3% |
| Biologics | 1018 | 50.8% | 313 | 32.1% | 22 | 42.3% | 1353 | 44.7% |
| Infliximab | 887 | 44.3% | 338 | 34.7% | 20 | 38.5% | 1245 | 41.1% |
| Adalimumab | 814 | 40.6% | 200 | 20.5% | 16 | 30.8% | 1030 | 34.0% |
| Vedolizumab | 323 | 16.1% | 190 | 19.5% | 10 | 19.2% | 523 | 17.3% |
| Ustekinumab | 213 | 10.6% | 15 | 1.5% | 3 | 5.8% | 231 | 7.6% |
| Certolizumab Pegol | 202 | 10.1% | 8 | 0.8% | 5 | 9.6% | 215 | 7.1% |
| Golimumab | 16 | 0.8% | 24 | 2.5% | 0 | 0.0% | 40 | 1.3% |
| Natalizumab | 34 | 1.7% | 1 | 0.1% | 0 | 0.0% | 35 | 1.2% |
| Immunomodulators | 395 | 19.7% | 111 | 11.4% | 11 | 21.2% | 517 | 17.1% |
| Thiopurine | 945 | 47.2% | 373 | 38.3% | 20 | 38.5% | 1338 | 44.2% |
| Methotrexate | 390 | 19.5% | 90 | 9.2% | 8 | 15.4% | 488 | 16.1% |
| Tofacitinib | 8 | 0.4% | 25 | 2.6% | 5 | 9.6% | 38 | 1.3% |
| Steroid Therapies | 1205 | 60.2% | 629 | 64.6% | 37 | 71.2 | 1871 | 61.8% |
| . | Crohn’s Disease . | . | Ulcerative Colitis . | . | IBD Unclassified . | . | Total . | . |
|---|---|---|---|---|---|---|---|---|
| . | N . | % . | N . | % . | N . | % . | N . | % . |
| . | 2003 . | 100.0% . | 974 . | 100.0% . | 52 . | 100.0% . | 3029 . | 100.0% . |
| At time of enrollment | ||||||||
| Aminosalicylates | 169 | 8.4% | 350 | 35.9% | 17 | 32.7% | 536 | 17.7% |
| Mesalamine | 132 | 6.6% | 301 | 30.9% | 15 | 28.8% | 448 | 14.8% |
| Sulfasalazine | 31 | 1.5% | 37 | 3.8% | 2 | 3.8% | 70 | 2.3% |
| Balsalazide | 9 | 0.4% | 28 | 2.9% | 0 | 0.0% | 37 | 1.2% |
| Biologics | 1147 | 57.3% | 372 | 38.2% | 19 | 36.5% | 1538 | 50.8% |
| Infliximab | 365 | 18.2% | 173 | 17.8% | 6 | 11.5% | 544 | 18.0% |
| Adalimumab | 335 | 16.7% | 64 | 6.6% | 6 | 11.5% | 405 | 13.4% |
| Vedolizumab | 167 | 8.3% | 115 | 11.8% | 4 | 7.7% | 286 | 9.4% |
| Ustekinumab | 236 | 11.8% | 9 | 0.9% | 2 | 3.8% | 247 | 8.2% |
| Certolizumab Pegol | 39 | 1.9% | 2 | 0.2% | 1 | 1.9% | 42 | 1.4% |
| Golimumab | 3 | 0.1% | 9 | 0.9% | 0 | 0.0% | 12 | 0.4% |
| Natalizumab | 2 | 0.1% | 0 | 0.0% | 0 | 0.0% | 2 | 0.1% |
| Immunomodulators | 458 | 22.9% | 221 | 22.7% | 13 | 25.0% | 692 | 22.8% |
| Azathioprine | 254 | 12.7% | 135 | 13.9% | 5 | 9.6% | 394 | 13.0% |
| Methotrexate | 115 | 5.7% | 34 | 3.5% | 6 | 11.5% | 155 | 5.1% |
| Mercaptopurine | 86 | 4.3% | 28 | 2.9% | 0 | 0.0% | 114 | 3.8% |
| Tofacitinib | 4 | 0.2% | 22 | 2.3% | 1 | 1.9% | 27 | 0.9% |
| Tacrolimus | 1 | 0.0% | 3 | 0.3% | 1 | 1.9% | 5 | 0.2% |
| Steroid Therapies | 151 | 7.5% | 111 | 11.4% | 5 | 9.6% | 267 | 8.8 |
| Exposure | ||||||||
| Aminosalicylates | 898 | 44.8% | 612 | 62.8% | 38 | 73.1% | 1548 | 51.1% |
| Mesalamine | 829 | 41.4% | 587 | 60.3% | 37 | 71.2% | 1453 | 48.0% |
| Sulfasalazine | 195 | 9.7% | 134 | 13.8% | 12 | 23.1% | 341 | 11.3% |
| Biologics | 1018 | 50.8% | 313 | 32.1% | 22 | 42.3% | 1353 | 44.7% |
| Infliximab | 887 | 44.3% | 338 | 34.7% | 20 | 38.5% | 1245 | 41.1% |
| Adalimumab | 814 | 40.6% | 200 | 20.5% | 16 | 30.8% | 1030 | 34.0% |
| Vedolizumab | 323 | 16.1% | 190 | 19.5% | 10 | 19.2% | 523 | 17.3% |
| Ustekinumab | 213 | 10.6% | 15 | 1.5% | 3 | 5.8% | 231 | 7.6% |
| Certolizumab Pegol | 202 | 10.1% | 8 | 0.8% | 5 | 9.6% | 215 | 7.1% |
| Golimumab | 16 | 0.8% | 24 | 2.5% | 0 | 0.0% | 40 | 1.3% |
| Natalizumab | 34 | 1.7% | 1 | 0.1% | 0 | 0.0% | 35 | 1.2% |
| Immunomodulators | 395 | 19.7% | 111 | 11.4% | 11 | 21.2% | 517 | 17.1% |
| Thiopurine | 945 | 47.2% | 373 | 38.3% | 20 | 38.5% | 1338 | 44.2% |
| Methotrexate | 390 | 19.5% | 90 | 9.2% | 8 | 15.4% | 488 | 16.1% |
| Tofacitinib | 8 | 0.4% | 25 | 2.6% | 5 | 9.6% | 38 | 1.3% |
| Steroid Therapies | 1205 | 60.2% | 629 | 64.6% | 37 | 71.2 | 1871 | 61.8% |
| . | Crohn’s Disease . | . | Ulcerative Colitis . | . | IBD Unclassified . | . | Total . | . |
|---|---|---|---|---|---|---|---|---|
| . | N . | % . | N . | % . | N . | % . | N . | % . |
| . | 2003 . | 100.0% . | 974 . | 100.0% . | 52 . | 100.0% . | 3029 . | 100.0% . |
| At time of enrollment | ||||||||
| Aminosalicylates | 169 | 8.4% | 350 | 35.9% | 17 | 32.7% | 536 | 17.7% |
| Mesalamine | 132 | 6.6% | 301 | 30.9% | 15 | 28.8% | 448 | 14.8% |
| Sulfasalazine | 31 | 1.5% | 37 | 3.8% | 2 | 3.8% | 70 | 2.3% |
| Balsalazide | 9 | 0.4% | 28 | 2.9% | 0 | 0.0% | 37 | 1.2% |
| Biologics | 1147 | 57.3% | 372 | 38.2% | 19 | 36.5% | 1538 | 50.8% |
| Infliximab | 365 | 18.2% | 173 | 17.8% | 6 | 11.5% | 544 | 18.0% |
| Adalimumab | 335 | 16.7% | 64 | 6.6% | 6 | 11.5% | 405 | 13.4% |
| Vedolizumab | 167 | 8.3% | 115 | 11.8% | 4 | 7.7% | 286 | 9.4% |
| Ustekinumab | 236 | 11.8% | 9 | 0.9% | 2 | 3.8% | 247 | 8.2% |
| Certolizumab Pegol | 39 | 1.9% | 2 | 0.2% | 1 | 1.9% | 42 | 1.4% |
| Golimumab | 3 | 0.1% | 9 | 0.9% | 0 | 0.0% | 12 | 0.4% |
| Natalizumab | 2 | 0.1% | 0 | 0.0% | 0 | 0.0% | 2 | 0.1% |
| Immunomodulators | 458 | 22.9% | 221 | 22.7% | 13 | 25.0% | 692 | 22.8% |
| Azathioprine | 254 | 12.7% | 135 | 13.9% | 5 | 9.6% | 394 | 13.0% |
| Methotrexate | 115 | 5.7% | 34 | 3.5% | 6 | 11.5% | 155 | 5.1% |
| Mercaptopurine | 86 | 4.3% | 28 | 2.9% | 0 | 0.0% | 114 | 3.8% |
| Tofacitinib | 4 | 0.2% | 22 | 2.3% | 1 | 1.9% | 27 | 0.9% |
| Tacrolimus | 1 | 0.0% | 3 | 0.3% | 1 | 1.9% | 5 | 0.2% |
| Steroid Therapies | 151 | 7.5% | 111 | 11.4% | 5 | 9.6% | 267 | 8.8 |
| Exposure | ||||||||
| Aminosalicylates | 898 | 44.8% | 612 | 62.8% | 38 | 73.1% | 1548 | 51.1% |
| Mesalamine | 829 | 41.4% | 587 | 60.3% | 37 | 71.2% | 1453 | 48.0% |
| Sulfasalazine | 195 | 9.7% | 134 | 13.8% | 12 | 23.1% | 341 | 11.3% |
| Biologics | 1018 | 50.8% | 313 | 32.1% | 22 | 42.3% | 1353 | 44.7% |
| Infliximab | 887 | 44.3% | 338 | 34.7% | 20 | 38.5% | 1245 | 41.1% |
| Adalimumab | 814 | 40.6% | 200 | 20.5% | 16 | 30.8% | 1030 | 34.0% |
| Vedolizumab | 323 | 16.1% | 190 | 19.5% | 10 | 19.2% | 523 | 17.3% |
| Ustekinumab | 213 | 10.6% | 15 | 1.5% | 3 | 5.8% | 231 | 7.6% |
| Certolizumab Pegol | 202 | 10.1% | 8 | 0.8% | 5 | 9.6% | 215 | 7.1% |
| Golimumab | 16 | 0.8% | 24 | 2.5% | 0 | 0.0% | 40 | 1.3% |
| Natalizumab | 34 | 1.7% | 1 | 0.1% | 0 | 0.0% | 35 | 1.2% |
| Immunomodulators | 395 | 19.7% | 111 | 11.4% | 11 | 21.2% | 517 | 17.1% |
| Thiopurine | 945 | 47.2% | 373 | 38.3% | 20 | 38.5% | 1338 | 44.2% |
| Methotrexate | 390 | 19.5% | 90 | 9.2% | 8 | 15.4% | 488 | 16.1% |
| Tofacitinib | 8 | 0.4% | 25 | 2.6% | 5 | 9.6% | 38 | 1.3% |
| Steroid Therapies | 1205 | 60.2% | 629 | 64.6% | 37 | 71.2 | 1871 | 61.8% |
| . | Crohn’s Disease . | . | Ulcerative Colitis . | . | IBD Unclassified . | . | Total . | . |
|---|---|---|---|---|---|---|---|---|
| . | N . | % . | N . | % . | N . | % . | N . | % . |
| . | 2003 . | 100.0% . | 974 . | 100.0% . | 52 . | 100.0% . | 3029 . | 100.0% . |
| At time of enrollment | ||||||||
| Aminosalicylates | 169 | 8.4% | 350 | 35.9% | 17 | 32.7% | 536 | 17.7% |
| Mesalamine | 132 | 6.6% | 301 | 30.9% | 15 | 28.8% | 448 | 14.8% |
| Sulfasalazine | 31 | 1.5% | 37 | 3.8% | 2 | 3.8% | 70 | 2.3% |
| Balsalazide | 9 | 0.4% | 28 | 2.9% | 0 | 0.0% | 37 | 1.2% |
| Biologics | 1147 | 57.3% | 372 | 38.2% | 19 | 36.5% | 1538 | 50.8% |
| Infliximab | 365 | 18.2% | 173 | 17.8% | 6 | 11.5% | 544 | 18.0% |
| Adalimumab | 335 | 16.7% | 64 | 6.6% | 6 | 11.5% | 405 | 13.4% |
| Vedolizumab | 167 | 8.3% | 115 | 11.8% | 4 | 7.7% | 286 | 9.4% |
| Ustekinumab | 236 | 11.8% | 9 | 0.9% | 2 | 3.8% | 247 | 8.2% |
| Certolizumab Pegol | 39 | 1.9% | 2 | 0.2% | 1 | 1.9% | 42 | 1.4% |
| Golimumab | 3 | 0.1% | 9 | 0.9% | 0 | 0.0% | 12 | 0.4% |
| Natalizumab | 2 | 0.1% | 0 | 0.0% | 0 | 0.0% | 2 | 0.1% |
| Immunomodulators | 458 | 22.9% | 221 | 22.7% | 13 | 25.0% | 692 | 22.8% |
| Azathioprine | 254 | 12.7% | 135 | 13.9% | 5 | 9.6% | 394 | 13.0% |
| Methotrexate | 115 | 5.7% | 34 | 3.5% | 6 | 11.5% | 155 | 5.1% |
| Mercaptopurine | 86 | 4.3% | 28 | 2.9% | 0 | 0.0% | 114 | 3.8% |
| Tofacitinib | 4 | 0.2% | 22 | 2.3% | 1 | 1.9% | 27 | 0.9% |
| Tacrolimus | 1 | 0.0% | 3 | 0.3% | 1 | 1.9% | 5 | 0.2% |
| Steroid Therapies | 151 | 7.5% | 111 | 11.4% | 5 | 9.6% | 267 | 8.8 |
| Exposure | ||||||||
| Aminosalicylates | 898 | 44.8% | 612 | 62.8% | 38 | 73.1% | 1548 | 51.1% |
| Mesalamine | 829 | 41.4% | 587 | 60.3% | 37 | 71.2% | 1453 | 48.0% |
| Sulfasalazine | 195 | 9.7% | 134 | 13.8% | 12 | 23.1% | 341 | 11.3% |
| Biologics | 1018 | 50.8% | 313 | 32.1% | 22 | 42.3% | 1353 | 44.7% |
| Infliximab | 887 | 44.3% | 338 | 34.7% | 20 | 38.5% | 1245 | 41.1% |
| Adalimumab | 814 | 40.6% | 200 | 20.5% | 16 | 30.8% | 1030 | 34.0% |
| Vedolizumab | 323 | 16.1% | 190 | 19.5% | 10 | 19.2% | 523 | 17.3% |
| Ustekinumab | 213 | 10.6% | 15 | 1.5% | 3 | 5.8% | 231 | 7.6% |
| Certolizumab Pegol | 202 | 10.1% | 8 | 0.8% | 5 | 9.6% | 215 | 7.1% |
| Golimumab | 16 | 0.8% | 24 | 2.5% | 0 | 0.0% | 40 | 1.3% |
| Natalizumab | 34 | 1.7% | 1 | 0.1% | 0 | 0.0% | 35 | 1.2% |
| Immunomodulators | 395 | 19.7% | 111 | 11.4% | 11 | 21.2% | 517 | 17.1% |
| Thiopurine | 945 | 47.2% | 373 | 38.3% | 20 | 38.5% | 1338 | 44.2% |
| Methotrexate | 390 | 19.5% | 90 | 9.2% | 8 | 15.4% | 488 | 16.1% |
| Tofacitinib | 8 | 0.4% | 25 | 2.6% | 5 | 9.6% | 38 | 1.3% |
| Steroid Therapies | 1205 | 60.2% | 629 | 64.6% | 37 | 71.2 | 1871 | 61.8% |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
